{"id":88779,"date":"2019-03-19T10:22:24","date_gmt":"2019-03-19T17:22:24","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2019\/03\/restorbio-announces-phase-3-human-trials"},"modified":"2019-03-19T10:22:24","modified_gmt":"2019-03-19T17:22:24","slug":"restorbio-announces-phase-3-human-trials","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2019\/03\/restorbio-announces-phase-3-human-trials","title":{"rendered":"ResTORbio Announces Phase 3 Human Trials"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/restorbio-announces-phase-3-human-trials.jpg\"><\/a><\/p>\n<p>Last year, resTORbio announced the positive results of its <a href=\"https:\/\/www.leafscience.org\/restorbio-announces-results-in-phase-2b-human-trial\/\">phase 2b human trial<\/a>, which targeted the aging immune system with an immune system-boosting drug. Now, the company has announced the news that its therapy is moving to a phase 3 study later this year after successful negotiation with the FDA.<\/p>\n<p><strong>Targeting the mTOR pathway of aging<\/strong><\/p>\n<p>ResTORbio is a biopharmaceutical company that is developing therapies that directly target the aging processes in order to prevent or cure age-related diseases. Its primary candidate drug is RTB101, which targets part of the mTOR pathway, one of the <a href=\"https:\/\/www.leafscience.org\/deregulated-nutrient-sensing\/\">pathways involved in aging<\/a>.<\/p>\n<p><!-- Link: <a href=\"https:\/\/www.leafscience.org\/restorbio-announces-phase-3-human-trials\/\">https:\/\/www.leafscience.org\/restorbio-announces-phase-3-human-trials\/<\/a> --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Last year, resTORbio announced the positive results of its phase 2b human trial, which targeted the aging immune system with an immune system-boosting drug. Now, the company has announced the news that its therapy is moving to a phase 3 study later this year after successful negotiation with the FDA. Targeting the mTOR pathway of [\u2026]<\/p>\n","protected":false},"author":370,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,269],"tags":[],"class_list":["post-88779","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-life-extension"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/88779","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/370"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=88779"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/88779\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=88779"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=88779"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=88779"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}